TY - JOUR
AU - Altman, Russ
AB - PharmGKB summary 979 d a b c Connie Oshiro , Sharon Marsh , Howard McLeod , Michelle Whirl Carrillo , d d,e Teri Klein and Russ Altman Pharmacogenetics and Genomics 2009, 19:979–983 Correspondence to Dr Teri E. Klein, PhD, Department of Genetics, Stanford University Medical Center, 300 Pasteur D. Lane L301, Mail Code 5120, Stanford, Keywords: abraxane, docetaxel, paclitaxel, taxane, taxol CA 94305-5120, USA Tel: + 1 650 725 0659; fax: + 1 650 725 3863; Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, e-mail: feedback@pharmgkb.org Montreal, Quebec Canada, Institute for Pharmacogenomics and Individualized Therapy, CA, University of North Carolina, Chapel Hill, NC, 23andMe, Inc., Received 29 July 2009 Accepted 22 September 2009 Mountain View, Department of Genetics, Stanford University and Bioengineering, Stanford University Medical Center, Stanford, California, USA Overview linear pharmacokinetics but paclitaxel did not [2,12]. Taxanes, such as paclitaxel and docetaxel, are widely However, the two taxanes have different formulations: prescribed chemotherapeutic drugs [1–3]. They have paclitaxel is dissolved in Cremaphor EL (CrEL, poly- been used to treat many forms of cancer including breast, oxyethyleneglycol triricinoleate 35)/ethanol (1 : 1) where ovarian, and lung cancers [1]. Paclitaxel was isolated as docetaxel is dissolved in polysorbate 80 (Tween 
TI - Taxane pathway
JF - Pharmacogenetics & Genomics
DO - 10.1097/FPC.0b013e3283335277
DA - 2009-12-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/taxane-pathway-wdUwO1dF65
SP - 979
EP - 983
VL - 19
IS - 12
DP - DeepDyve
ER -